Today's special offer: Access for Free!!!

GlaxoSmithKline PLC (GSK) | Statement of Financial Position, Assets

See also

ˇ Show More

The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

You have visited 10 password protected pages for free. Others contain data covered by .

Sign Up Now to get full access to whole website and cut out all advertisements.

GlaxoSmithKline PLC, Consolidated Statement of Financial Position, Assets

USD $ in millions, translated from GBP £

Export to Excel Export to OpenOffice.org
    Dec 31, 2011 Dec 31, 2010 Dec 31, 2009 Dec 31, 2008 Dec 31, 2007
chart Property, plant and equipment
chart Goodwill
chart Other intangible assets
chart Joint ventures
chart Associated undertakings
chart Investments in associates and joint ventures
chart Other investments
chart Deferred tax assets
chart Derivative financial instruments
chart Amounts receivable under insurance contracts
chart Pension schemes in surplus
chart Other receivables
chart Other non-current assets
chart Non-current assets
chart Inventories
chart Current tax recoverable
chart Trade receivables, net of provision for bad and doubtful debts
chart Prepaid pension contributions
chart Other prepayments and accrued income
chart Interest receivable
chart Employee loans and advances
chart Other receivables
chart Trade and other receivables
chart Derivative financial instruments
chart Liquid investments
chart Cash and cash equivalents
chart Assets held for sale
chart Current assets
chart Total assets
Source: GlaxoSmithKline PLC, Annual Reports
Item Description The company
Property, plant and equipment Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment. GlaxoSmithKline PLC's property, plant and equipment declined from 2009 to 2010 and from 2010 to 2011.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. GlaxoSmithKline PLC's non-current assets declined from 2009 to 2010 and from 2010 to 2011.
Inventories Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer). GlaxoSmithKline PLC's inventories declined from 2009 to 2010 but then slightly increased from 2010 to 2011.
Trade receivables, net of provision for bad and doubtful debts Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. GlaxoSmithKline PLC's trade receivables, net of provision for bad and doubtful debts declined from 2009 to 2010 and from 2010 to 2011.
Liquid investments Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer. GlaxoSmithKline PLC's liquid investments declined from 2009 to 2010 but then slightly increased from 2010 to 2011.
Cash and cash equivalents Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. GlaxoSmithKline PLC's cash and cash equivalents declined from 2009 to 2010 and from 2010 to 2011.
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. GlaxoSmithKline PLC's current assets declined from 2009 to 2010 but then slightly increased from 2010 to 2011.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. GlaxoSmithKline PLC's total assets declined from 2009 to 2010 and from 2010 to 2011.

Top

Stock Analysis on Net (www.stock-analysis-on.net)
Copyright © 2012 EBIT Financial Analyses Center